FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385198001> ?p ?o ?g. }

• W4385198001 endingPage "463" @default.
• W4385198001 startingPage "463" @default.
• W4385198001 abstract "Background and Aims: Zonulin, carnitine, choline, g-butyrobetaine (g-BB), and trimethylamine N-oxide (TMAO) are intricately involved in metabolic anomalies and type 2 diabetes mellitus (T2D). This study aimed to compare and correlate the plasma levels of zonulin, carnitine, choline, g-butyrobetaine, and TMAO, along with the adiposity, atherogenicity, surrogate insulin resistance (sIR), and proinflammatory hematological indices of newly diagnosed drug-naive pre-diabetic and diabetic patients vs. apparently healthy normoglycemic controls.&#x0D; Methods: In a cross-sectional study, 30 normoglycemic subjects (controls) and 16 pre-diabetic (PreDM) and 14 type 2 diabetes (T2D) cases, that were gender and age-matched, were enrolled. Zonulin, carnitine, choline, g-BB, and TMAO plasma levels were appraised using colorimetric assays. A comparison between the study groups was conducted by ANOVA while Spearman rank correlations between the metabolic risk biomarkers and between the risk markers and adiposity, sIR, atherogenicity, and proinflammatory hematological indices were also examined.&#x0D; Results: Significant intergroup discrepancies in plasma carnitine, choline, g-BB, and TMAO (but not zonulin) could be recognized in the cases vs. controls. Fasting blood glucose (FPG), glycated hemoglobin (A1C), triglycerides (TG), body mass index (BMI), lipid accumulation product (LAP), visceral adiposity index (VAI), atherogenic index of plasma (AIP), and all sIR were outstandingly higher in the cases vs. controls. Blood indices lacked a scoring value to discriminate cases from controls. Inadvertently, no relation was found between plasma carnitine, choline, g-BB, TMAO, or zonulin in cases. Among the rest of the markers and sIR indices; The triglyceride-glucose-body mass index (TyG*BMI) related reciprocally to zonulin. Noticeably, among adiposity indices, TyG*BMI, triglyceride glucose-waist circumference (TyG*WC), and metabolic score for insulin resistance (MetS-IR) positively associated with waist circumference (WC), hip circumference (HC), BMI, body adiposity index (BAI), and waist-to-height ratio (WHtR). Exceptionally LAP proportionally correlated with all sIR. TyG*WC and MetS-IR correlated directly with the conicity index (CI). WHR directly associated with triglyceride-glucose (TyG) index and TyG*WC. Remarkably, the TyG index (but not TyG*BMI, TyG*WC, or MetS-IR) positively associated with all atherogenicity indices and RDW (but none of other blood indices). TMAO correlated inversely (P < 0.05) and moderately with choline. Distinctively, carnitine associated negatively with TC (P < 0.05). Both choline and carnitine related similarly and directly with PLR but inversely with lymphocytes (p <0.05). Effectively, gButyrobetaine associated with both WC and the TyG-WC index equally negatively (P < 0.05). Substantially, gButyrobetaine correlated inversely with both atherogenic LDL-C/HDL-C ratio and MPV (P < 0.05). No pronounced relations were detected between the five microbiome signature determinants and glycemic control parameters (FBG and A1C %), sIR (TyG, TyG-BMI or MetS-IR), adiposity (WHR, WHtR, CI, BAI, LAP, or VAI), atherogenicity indices (TC/HDL-C ratio, non‑HDL‑C/HDL-C ratio, or AIP), or blood indices (NLR or MLR).Conclusion: Given the intergroup discrepancies in sIR, plasma zonulin, carnitine, choline, g-BB, and TMAO along with their elective correlations with indices and clinical parameters of metabolic dysregulations, our study cannot rule out any possible molecular crosstalk and interplay of the biomarkers studied with the pathophysiology of prediabetes/diabetes. All in all, plasma zonulin, carnitine, choline, g-BB, and TMAO with sIR can be putative surrogates for molecular cardiometabolic risk biomarkers to use as prognostic/predictive tools for the diagnosis/prevention and potential targets for prediabetes/diabetes management modalities." @default.
• W4385198001 created "2023-07-25" @default.
• W4385198001 creator A5023712780 @default.
• W4385198001 date "2023-07-24" @default.
• W4385198001 modified "2023-09-28" @default.
• W4385198001 title "Plasma Carnitine, Choline, -Butyrobetaine, and Trimethylamine N-oxide, but not Zonulin, are reduced in overweight/obese Patients with Pre/diabetes or Impaired Glycemia" @default.
• W4385198001 doi "https://doi.org/10.35516/jjps.v16i2.1503" @default.
• W4385198001 hasPublicationYear "2023" @default.
• W4385198001 type Work @default.
• W4385198001 citedByCount "0" @default.
• W4385198001 crossrefType "journal-article" @default.
• W4385198001 hasAuthorship W4385198001A5023712780 @default.
• W4385198001 hasBestOaLocation W43851980011 @default.
• W4385198001 hasConcept C126322002 @default.
• W4385198001 hasConcept C134018914 @default.
• W4385198001 hasConcept C185592680 @default.
• W4385198001 hasConcept C2776149385 @default.
• W4385198001 hasConcept C2777180221 @default.
• W4385198001 hasConcept C2777391703 @default.
• W4385198001 hasConcept C2778163477 @default.
• W4385198001 hasConcept C2778270857 @default.
• W4385198001 hasConcept C2778435403 @default.
• W4385198001 hasConcept C2778913445 @default.
• W4385198001 hasConcept C2780221984 @default.
• W4385198001 hasConcept C2780578515 @default.
• W4385198001 hasConcept C2780924926 @default.
• W4385198001 hasConcept C2781123555 @default.
• W4385198001 hasConcept C2910068830 @default.
• W4385198001 hasConcept C55493867 @default.
• W4385198001 hasConcept C555293320 @default.
• W4385198001 hasConcept C71924100 @default.
• W4385198001 hasConceptScore W4385198001C126322002 @default.
• W4385198001 hasConceptScore W4385198001C134018914 @default.
• W4385198001 hasConceptScore W4385198001C185592680 @default.
• W4385198001 hasConceptScore W4385198001C2776149385 @default.
• W4385198001 hasConceptScore W4385198001C2777180221 @default.
• W4385198001 hasConceptScore W4385198001C2777391703 @default.
• W4385198001 hasConceptScore W4385198001C2778163477 @default.
• W4385198001 hasConceptScore W4385198001C2778270857 @default.
• W4385198001 hasConceptScore W4385198001C2778435403 @default.
• W4385198001 hasConceptScore W4385198001C2778913445 @default.
• W4385198001 hasConceptScore W4385198001C2780221984 @default.
• W4385198001 hasConceptScore W4385198001C2780578515 @default.
• W4385198001 hasConceptScore W4385198001C2780924926 @default.
• W4385198001 hasConceptScore W4385198001C2781123555 @default.
• W4385198001 hasConceptScore W4385198001C2910068830 @default.
• W4385198001 hasConceptScore W4385198001C55493867 @default.
• W4385198001 hasConceptScore W4385198001C555293320 @default.
• W4385198001 hasConceptScore W4385198001C71924100 @default.
• W4385198001 hasIssue "2" @default.
• W4385198001 hasLocation W43851980011 @default.
• W4385198001 hasOpenAccess W4385198001 @default.
• W4385198001 hasPrimaryLocation W43851980011 @default.
• W4385198001 hasRelatedWork W1894700821 @default.
• W4385198001 hasRelatedWork W1997338705 @default.
• W4385198001 hasRelatedWork W1998434356 @default.
• W4385198001 hasRelatedWork W2125102063 @default.
• W4385198001 hasRelatedWork W2143004231 @default.
• W4385198001 hasRelatedWork W2163591087 @default.
• W4385198001 hasRelatedWork W2347839228 @default.
• W4385198001 hasRelatedWork W2355237636 @default.
• W4385198001 hasRelatedWork W2370591872 @default.
• W4385198001 hasRelatedWork W2796825901 @default.
• W4385198001 hasVolume "16" @default.
• W4385198001 isParatext "false" @default.
• W4385198001 isRetracted "false" @default.
• W4385198001 workType "article" @default.